Attovia Therapeutics filed for an initial public offering and applied to list its shares on the Nasdaq Global Market under the ticker “ATTO.” The clinical-stage biopharmaceutical company develops next‑generation biologics for immune‑mediated diseases using its ATTOBODY platform. The filing does not disclose a price range or the number of shares to be offered.
Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next‑generation biologics for immune‑mediated diseases. Its proprietary ATTOBODY platform uses biparatopic VHH-based binders that can be modularly assembled into mono-, bi-, and trispecific formats designed for high potency, precision epitope targeting, and extended dosing intervals. The lead program, ATTO‑1310, is an anti‑IL‑31 Fc‑fusion being developed for chronic pruritic diseases such as chronic pruritus of unknown origin (CPUO), high‑itch atopic dermatitis, cholestatic pruritus, and CKD-associated pruritus. ATTO‑2306 is a bispecific that targets IL‑13 and IL‑31 for atopic dermatitis and other inflammatory skin diseases, and ATTO‑1091 is a trispecific that targets TL1A, IL‑23, and integrin α4β7 for inflammatory bowel disease.
The company’s strategy centers on clinically validated pathways with potential to improve efficacy and patient convenience through infrequent subcutaneous dosing. Attovia complements internal discovery with strategic licenses, including its foundational ATTOBODY platform in‑licensed from Alamar Biosciences, and an out‑license of radioligand applications to EndPath. Revenue to date comes from collaboration activities; the company has not yet generated product sales.
- Total addressable market: Atopic dermatitis projected to affect 21 million adults and 10 million pediatric patients in the U.S. by 2035; chronic pruritus population estimated at over 15 million by 2035
- Market growth: Global IBD market valued at $29.5 billion in 2025; DUPIXENT posted $17.8 billion sales in 2025 with ~18% penetration in moderate-to-severe AD
- Market position: Focus on pruritic and inflammatory diseases with clinically validated targets (IL‑31, IL‑13, TL1A, IL‑23, and integrin α4β7) and differentiated multispecific biologics
- Key competitors: Sanofi/Regeneron (DUPIXENT), Eli Lilly/Almirall (ADBRY/tralokinumab), Eli Lilly (lebrikizumab/EBGLYSS), Galderma/Chugai (nemolizumab/NEMLUVIO), AbbVie (RINVOQ), Pfizer (CIBINQO)
- Industry trends: Shift to targeted biologics and multispecifics, precision immunology, biomarker-driven development, and longer-interval subcutaneous dosing
- Customers: Collaboration revenue from EndPath radioligand license and services; no product sales to date
- Locations: Headquarters and R&D in San Carlos, California
- Geographic presence: U.S.-based operations with clinical activity in the United States and Canada
- Partnerships: Platform license from Alamar Biosciences; exclusive radioligand license to EndPath; third‑party manufacturing with global CDMOs
- Orders/GMV: Not applicable (pre‑commercial)
- Other key metrics: 44 full‑time employees as of June 30, 2026; $255.8 million raised since inception
- Revenue (current): $1.35 million (2025 collaboration revenue)
- Revenue growth: Increased from $0 in 2024 to $1.35 million in 2025
- Operating income: $(67.2) million loss (2025)
- Net income: $(60.6) million net loss (2025)
- Tao Fu, Chief Executive Officer and President - Former President/COO and Chief Strategy Officer at Zai Lab; prior leadership roles at Portola, BMS, and J&J.
- Zaneta Odrowaz, Ph.D., Chief Business Officer - Former Senior Director of Corporate Development at Amunix; earlier at Philips Neuro and McKinsey; Company co‑founder.
- Steven Chan, Chief Financial Officer - Former CFO at Connect Biopharma and Delphon; prior finance leadership at Arcus and MyoKardia.
- Petter Veiby, Chief Scientific Officer - Former Global Head of Biotherapeutics at Takeda Oncology; extensive discovery and development leadership; Company co‑founder.
- Hubert Chen, M.D., Chief Medical Officer - Former SVP, Clinical Development at Krystal Biotech; prior clinical leadership at Genentech; board‑certified in pulmonary and critical care.
- Issuer: Attovia Therapeutics, Inc.
- Filing date: July 14, 2026
- Proposed ticker: ATTO
- Exchange: Nasdaq Global Market
- Lead underwriters: Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets; LifeSci Capital
- Use of proceeds: Advance clinical development of ATTO-1310 and ATTO-2306, progress ATTO-1091 and research pipeline, and for working capital and general corporate purposes.
Original SEC Filing: Attovia Therapeutics, Inc. - S-1 - Jul. 14, 2026